Mafi yawa daga cikin sakamakon gwaje-gwaje na magunguna a kasar Sin da aka ƙirƙira

Pharmaceutical kamfanoni a kasar Sin ƙirƙira su gwajinsu samun amincewar jama'a game da kwayoyi da suka nuna. Wannan ƙarshe da aka sanya a cikin rahoton na Jihar Administration na Food and Drug Administration na kasar (SFDA). gwamnatin bincike ya kai ga mai ban mamaki sakamakon: game da 80% na dukkan data buga ta Sin masana'antun da kwayoyi yiwuwa an gurbata.

Mẽne ne game da rahoton

Bisa ga Sin jaridar tattalin arziki Information Daily, 1622 da aka yi karatu sakamakon gwajinsu da kwayoyi jiran amincewa. An gano cewa mafi yawan wadannan binciken ko ba za a iya tabbatar, ko su ne bai cika ko gaza bada haɗin kai ga zama dole matsayin for analysis. A SFDA ce cewa da karfi tattalin arziki gasar da kuma kudi matsin lamba na iya zama da babban dalili ga wannan fraudulent ayyuka, kamar yadda Pharmaceutical kamfanoni sukan cike take kokarin samun da koren haske don ya bashe su kai kayayyakinsu kasuwa.

Duk da haka, wannan ne sosai lalata hali iya yiwuwar samun m sakamakon ga wadanda suka zabi yin amfani da wadannan kwayoyi. Alal misali, wani rahoto ya nuna cewa da yawa kamfanonin da gangan rashin sanin cikakken farashi da illa samu da mahalarta a lokacin da nazari, a cikin bege da samun da zama dole yabo ga lafiya da aminci. SFDA la'anci yi a matsayin take hakkin wajibi da dubawa sassa da kuma malpractice a kan wani ɓangare na Pharmaceutical kamfanoni,-tsakin jamiái da kuma kiwon lafiya.

Ra'ayi na kasar ma'aikatan kiwon lafiya,

China Medical ma'aikacin Luo Liang ya shaidawa Radio "Free Asia", da cewa Pharmaceutical masana'antu a kasar Sin ta ~ uka komai a Amurka da Turai, wanda ke nufin cewa kamfanonin sau da yawa koma ga magudi lashe dama don ya bashe ta biyu-aji kwayoyi a kasuwa. A kasar Sin, akwai wani ci gaban da sabon kwayoyi da, kamar yadda za a iya gani a kasashen waje, ya ce, ya kara da cewa Sin pharmaceutical kamfanonin kullum saki kayayyakin amfani dabarbari, wanda da zarar ya patent, amma shi ya ƙare.